Voretigene neparvovec

DB13932ApprovedInvestigationalGene TherapiesAdeno-associated Viral Vector Therapies

Voretigene neparvovec is an adeno-associated viral gene therapy used to treat biallelic RPE65 mutation associated retinal dystrophy. An adeno-associated virus is a small virus that infects humans and other primates.

Protein structure of Voretigene neparvovec
Mechanism
Curator reviewed · 2 references
Primary indication
VN-rzyl is indicated for the treatment of children and adult patients with confirmed biallelic RPE65 mutation-associated retinal dystrophy.Curator reviewed · 1 structured indication
First approval
Canada, 2020 · United States, 2017 · European Union, 2020
Also known as
Recombinant adeno-associated virus retinal pigment epithelium gene vector AAV2-hRPE65v2 · VN-rzyl · Voretigene Neparvovec-rzyl
Brand names
  • Luxturna

Resolves to

What you can answer from here — as of March 06, 2025

1Protein targetEach mapped to UniProt, with action and pharmacological action
Listed above
6Clinical trialsPhase, status and sponsor resolved per trial
Sign in
1Structured indicationCondition, population, route and combination as fields, not prose
Sign in
1ContraindicationEach with its own population and attribute set
Sign in
4Marketed productsAcross 4 countries and 3 labellers
Sign in
1ATC codeIncluding every combination product, plus 3 drug categories
Sign in
10+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with Voretigene neparvovec, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.

Create Account